B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained its Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raised the price target from $248 to $295.
June 25, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has maintained its Buy rating on Alnylam Pharmaceuticals and increased the price target from $248 to $295, indicating strong confidence in the company's future performance.
The raised price target from $248 to $295 by B of A Securities suggests a positive outlook for Alnylam Pharmaceuticals. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100